80 FR 66015 - Prospective Grant of Exclusive License: Development of Therapeutics To Treat Obesity, Type 2 Diabetes, Fatty Liver Disease, and Liver Fibrosis in Humans

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 208 (October 28, 2015)

Page Range		66015-66015
FR Document		2015-27454

This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the following inventions embodied in the following patent applications, entitled ``CB1 receptor mediating compounds'':

Federal Register, Volume 80 Issue 208 (Wednesday, October 28, 2015)

[Federal Register Volume 80, Number 208 (Wednesday, October 28, 2015)]
[Notices]
[Page 66015]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-27454]



[[Page 66015]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Development of 
Therapeutics To Treat Obesity, Type 2 Diabetes, Fatty Liver Disease, 
and Liver Fibrosis in Humans

AGENCY: National Institutes of Diabetes and Digestive and Kidney 
Diseases, National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 
part 404.7, that the National Institutes of Health, Department of 
Health and Human Services, is contemplating the grant of an exclusive 
patent license to practice the following inventions embodied in the 
following patent applications, entitled ``CB1 receptor mediating 
compounds'':

1. U.S. Provisional Patent Application No.: 61/991,333
HHS Ref. No.: E-140-2014/0-US-01
Filed: May 09, 2014

2. PCT Application No.: PCT/US2015/029946
HHS Ref. No.: E-140-2014/0-PCT-02
Filed: May 08, 2015

3. U.S. Provisional Patent Application No.: 61/725,949
HHS Ref. No.: E-282-2012/0-US-01
Filed: November 13, 2012

4. PCT Application No.: PCT/US2013/069686
HHS Ref. No.: E-282-2012/0-PCT-02
Filed: November 12, 2013

5. U.S. Patent Application No.: 14/442,383
HHS Ref. No.: E-282-2012/0-US-03
Filed: May 12, 2015

6. Canadian Patent Application No.: 2889697
HHS Ref. No.: E-282-2012/0-CA-04
Filed: April 27, 2015

7. European Patent Application No.: 13802153.0
HHS Ref. No.: E-282-2012/0-EP-05
Filed: June 01, 2015

8. Indian Patent Application No.: 3733/DELNP/2015
HHS Ref. No.: E-282-2012/0-IN-06
Filed: May 01, 2015

9. Japanese Patent Application No.: 2015-542015
HHS Ref. No.: E-282-2012/0-JP-07
Filed: May 11, 2015

10. Chinese Patent Application No.: 201380069389.9
HHS Ref. No.: E-282-2012/0-CN-08
Filed: July 3, 2015

11. U.S. Provisional Application No.: 62/171,179
HHS Ref. No.: E-282-2012/1-US-01
Filed: June 04, 2015

to Inversago Pharma Inc., (``Inversago''), a company incorporated under 
the laws of Canada having an office in at least Montreal-Ouest, Quebec, 
Canada. The patent rights in these inventions have been assigned to the 
United States of America. This license may be worldwide. The field of 
use may be related to ``Development of therapeutics to treat obesity, 
type 2 diabetes, fatty liver disease and liver fibrosis in humans.''

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
November 12, 2015 will be considered.

ADDRESSES: Requests for copies of the patent application, patents, 
inquiries, comments, and other materials relating to the contemplated 
exclusive license should be directed to: Patrick McCue, Ph.D., Senior 
Licensing and Patenting Manager, Technology Advancement Office, The 
National Institute of Diabetes and Digestive and Kidney Diseases, 12A 
South Drive, Bethesda, MD 20892, Telephone: (301) 435-5560; Email: 
[email protected]. A signed confidentiality non-disclosure 
agreement will be required to receive copies of any patent applications 
that have not been published by the United States Patent and Trademark 
Office or the World Intellectual Property Organization.

SUPPLEMENTARY INFORMATION: This technology, and its corresponding 
patent applications, is directed to methods of treating obesity and 
associated diseases such as type 2 diabetes, hepatic steatosis, and 
liver fibrosis by administering an agent that reduces appetite, body 
weight, and insulin resistance. This technology may be useful as a 
means for treating obesity and metabolic syndrome without serious 
adverse neuropsychiatric side effects.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404.7. The prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR part 404.7.
    Properly-filed and complete competing applications for a license in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: October 19, 2015.
Anna Z. Amar,
Acting Deputy Director, Technology Advancement Office, National 
Institute of Diabetes and Digestive and Kidney, Diseases, National 
Institutes of Health.
[FR Doc. 2015-27454 Filed 10-27-15; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 80, No. 208 / Wednesday, October 28, 2015 / Notices 66015

DEPARTMENT OF HEALTH AND patent rights in these inventions have Dated: October 19, 2015.
HUMAN SERVICES been assigned to the United States of Anna Z. Amar,
America. This license may be Acting Deputy Director, Technology
National Institutes of Health worldwide. The field of use may be Advancement Office, National Institute of
related to ‘‘Development of therapeutics Diabetes and Digestive and Kidney, Diseases,
Prospective Grant of Exclusive to treat obesity, type 2 diabetes, fatty National Institutes of Health.
License: Development of Therapeutics liver disease and liver fibrosis in [FR Doc. 2015–27454 Filed 10–27–15; 8:45 am]
To Treat Obesity, Type 2 Diabetes, humans.’’ BILLING CODE 4140–01–P
Fatty Liver Disease, and Liver Fibrosis
in Humans DATES: Only written comments and/or
applications for a license which are
AGENCY: National Institutes of Diabetes DEPARTMENT OF HOMELAND
received by the NIH Office of
and Digestive and Kidney Diseases, SECURITY
Technology Transfer on or before
National Institutes of Health, Public November 12, 2015 will be considered.
Health Service, HHS. Coast Guard
ADDRESSES: Requests for copies of the
ACTION: Notice. [Docket No. USCG–2015–0805]
patent application, patents, inquiries,
SUMMARY: This notice, in accordance comments, and other materials relating National Offshore Safety Advisory
with 35 U.S.C. 209(c)(1) and 37 CFR to the contemplated exclusive license Committee
part 404.7, that the National Institutes of should be directed to: Patrick McCue,
Health, Department of Health and Ph.D., Senior Licensing and Patenting AGENCY:Coast Guard, DHS.
Human Services, is contemplating the Manager, Technology Advancement Notice of Federal Advisory
ACTION:
grant of an exclusive patent license to Office, The National Institute of Committee meeting.
practice the following inventions Diabetes and Digestive and Kidney
SUMMARY: The National Offshore Safety
embodied in the following patent Diseases, 12A South Drive, Bethesda,
Advisory Committee and its
applications, entitled ‘‘CB1 receptor MD 20892, Telephone: (301) 435–5560;
Subcommittee will hold a public
mediating compounds’’: Email: patrick.mccue@nih.gov. A signed
meeting in Katy, TX to discuss the
confidentiality non-disclosure
1. U.S. Provisional Patent Application No.: safety of operations and other matters
61/991,333
agreement will be required to receive
affecting the offshore oil and gas
HHS Ref. No.: E–140–2014/0–US–01 copies of any patent applications that
industry. These meetings are open to the
Filed: May 09, 2014 have not been published by the United
public.
2. PCT Application No.: PCT/US2015/029946 States Patent and Trademark Office or
the World Intellectual Property DATES: Subcommittees of the National
HHS Ref. No.: E–140–2014/0–PCT–02
Filed: May 08, 2015 Organization. Offshore Safety Advisory Committee
will meet on Wednesday, November 18,
3. U.S. Provisional Patent Application No.: SUPPLEMENTARY INFORMATION: This
61/725,949 2015 from 1 p.m. to 4 p.m. and the full
technology, and its corresponding Committee will meet on Thursday,
HHS Ref. No.: E–282–2012/0–US–01
Filed: November 13, 2012 patent applications, is directed to November 19, 2015, from 8:30 a.m. to
4. PCT Application No.: PCT/US2013/069686
methods of treating obesity and 4:30 p.m. (All times are Central
HHS Ref. No.: E–282–2012/0–PCT–02 associated diseases such as type 2 Standard Time). These meetings may
Filed: November 12, 2013 diabetes, hepatic steatosis, and liver end early if the Committee has
5. U.S. Patent Application No.: 14/442,383 fibrosis by administering an agent that completed its business, or they may be
HHS Ref. No.: E–282–2012/0–US–03 reduces appetite, body weight, and extended based on the number of public
Filed: May 12, 2015 insulin resistance. This technology may comments.
6. Canadian Patent Application No.: 2889697 be useful as a means for treating obesity ADDRESSES: The meetings will be held at
HHS Ref. No.: E–282–2012/0–CA–04 and metabolic syndrome without the Det Norske Veritas GL conference
Filed: April 27, 2015 serious adverse neuropsychiatric side facility located at 1400 Ravello Drive,
7. European Patent Application No.: effects. Katy, TX 77449.
13802153.0 The prospective exclusive license will For information on facilities or
HHS Ref. No.: E–282–2012/0–EP–05 be royalty bearing and will comply with services for individuals with
Filed: June 01, 2015 the terms and conditions of 35 U.S.C. disabilities, or to request special
8. Indian Patent Application No.: 3733/ 209 and 37 CFR part 404.7. The assistance at the meetings, contact the
DELNP/2015 prospective exclusive license may be
HHS Ref. No.: E–282–2012/0–IN–06 individuals listed in FOR FURTHER
Filed: May 01, 2015
granted unless within fifteen (15) days INFORMATION CONTACT section, as soon as
from the date of this published notice, possible.
9. Japanese Patent Application No.: 2015–
542015
the NIH receives written evidence and To facilitate public participation, we
HHS Ref. No.: E–282–2012/0–JP–07 argument that establishes that the grant are inviting public comment on the
Filed: May 11, 2015 of the license would not be consistent issues to be considered by the
10. Chinese Patent Application No.: with the requirements of 35 U.S.C. 209 Committee as listed in the ‘‘Agenda’’
201380069389.9 and 37 CFR part 404.7. section below. Written comments may
HHS Ref. No.: E–282–2012/0–CN–08 Properly-filed and complete be submitted using the Federal
Filed: July 3, 2015 competing applications for a license in eRulemaking Portal at http://
mstockstill on DSK4VPTVN1PROD with NOTICES

11. U.S. Provisional Application No.: 62/ response to this notice will be treated as www.regulations.gov. If your material
171,179 objections to the contemplated license. cannot be submitted using http://
HHS Ref. No.: E–282–2012/1–US–01 Comments and objections submitted in www.regulations.gov, contact the person
Filed: June 04, 2015 response to this notice will not be made in the FOR FURTHER INFORMATION
to Inversago Pharma Inc., (‘‘Inversago’’), available for public inspection and, to CONTACT section of this document for
a company incorporated under the laws the extent permitted by law, will not be alternate instructions.
of Canada having an office in at least released under the Freedom of Instructions: All submissions received
Montreal-Ouest, Quebec, Canada. The Information Act, 5 U.S.C. 552. must include the words ‘‘Department of

VerDate Sep<11>2014 19:16 Oct 27, 2015 Jkt 238001 PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 E:\FR\FM\28OCN1.SGM 28OCN1

Document Created: 2018-02-27 08:57:48
Document Modified: 2018-02-27 08:57:48

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Dates		Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 12, 2015 will be considered.
FR Citation		80 FR 66015

80 FR 66015 - Prospective Grant of Exclusive License: Development of Therapeutics To Treat Obesity, Type 2 Diabetes, Fatty Liver Disease, and Liver Fibrosis in Humans

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 80, Issue 208 (October 28, 2015)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health